Given that chemotherapy is the current standard line of treatment in osteosarcoma, it is important to add that CDK4 inhibition acts antagonistically to it and therefore strategies positioning CDK4 inhibitors between chemotherapy cycles are being developed to prevent survival of residual tumor cells that escape current chemotherapy regimens. Here, CDK4 is linked to neoplasm.